Clinical TrialJul 8, 2026, 06:31 AM
Satellos SAT-3247 TRAILHEAD: 3.7% fat fraction decline, 34% effort gain
AI Summary
Satellos Bioscience Inc. announced positive six-month interim data from its TRAILHEAD study for investigational drug SAT-3247 in adults with Duchenne muscular dystrophy. The results showed reduced muscle fat fraction, increased total upper limb effort, stable strength, and lower muscle damage biomarkers. The drug maintained a favorable safety profile, and the company plans to complete enrollment in its BASECAMP study and initiate US clinical trial sites for TRAILHEAD in the third quarter.
Key Highlights
- SAT-3247 showed a mean 3.7% decline in muscle fat fraction.
- Upper limb effort (TE99C) improved by approximately 34%.
- Handgrip strength maintained near-doubling from prior study.
- Mean creatine kinase (CK) declined 38% from baseline.
- Favorable safety profile with no serious treatment-emergent adverse events.
- PUL2.0 increased in two participants, stable in two.
- PedsQL-MFS quality of life scores increased by 6.94 points.
- Company to initiate US TRAILHEAD sites in Q3 this year.
Price Impact
More from MSLE